Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

Inclusion Criteria: * Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL) * High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification) * Burkitt's lymphoma (including atypical Burkitt's lymphoma) * Precursor B-lymphoblastic lymphoma * Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type) * Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma) * Age = 18 years * Patient's Informed Consent Exclusion Criteria: * Serious complications caused by leukemia/ lymphoma or by a second illness: e.g. * Severe, unmanageable complications such as sepsis, pneumonia with oxygen deficiency, * Shock, hemorrhage at the time of diagnosis * Renal insufficiency from leukemia/lymphoma-unrelated causes * Severe cardiac or hepatic insufficiency * Severe obstructive or restrictive lung disease that would compromise patient's treatment with intensified chemotherapy * HIV infection * Secondary lymphoma following prior chemotherapy/ radiotherapy or an active second malignancy * Known severe allergy to foreign proteins * Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of steroids = 7 days, single administration of vincristine or cyclophosphamide, one cycle of CHOP, a single administration in an emergency of other cytostatic agents) for another malignant disease within the last 5 years * Pregnancy/ nursing period * Severe psychiatric illness or other circumstances giving ground to the assumption that a patient cannot give his consent to therapy or act co-operatively * Absence of patient's informed consent * Participation in another clinical study that would possibly interfere with study therapy